A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (12 mg/kg) Administration in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus.

Trial Profile

A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (12 mg/kg) Administration in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2010

At a glance

  • Drugs Lisofylline (Primary) ; Lisofylline (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors DiaKine Therapeutics
  • Most Recent Events

    • 10 Aug 2010 Status changed from active, no longer recruiting to completed based on presenation of results at the 70th Annual Scientific Sessions of the American Diabetes Association.
    • 29 Jun 2010 Outcomes reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
    • 14 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top